By Josh White
Date: Thursday 31 Oct 2024
(Sharecast News) - Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the Gardasil HPV vaccine remained a challenge.
No recent information was found.
Currency | US Dollars |
Share Price | $ 99.86 |
Change Today | $ 2.42 |
% Change | 2.48 % |
52 Week High | $132.96 |
52 Week Low | $96.31 |
Volume | 15,631,800 |
Shares Issued | 2,531.63m |
Market Cap | $252,809m |
Beta | 0.19 |
RiskGrade | 92 |
Strong Buy | 10 |
Buy | 11 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 25 |
Time | Volume / Share Price |
15:59 | 100 @ $99.89 |
15:59 | 100 @ $99.88 |
15:59 | 184 @ $99.98 |
15:59 | 100 @ $99.98 |
15:59 | 184 @ $99.98 |
You are here: research